Healthcare

• Nucleus Nexa represented more than 95% of implant sales in developed markets by June 2026

Imricor Medical Systems (ASX:IMR) is developing a differentiated medical-technology platform designed to enable cardiac catheter ablation procedures to be performed under magnetic resonance imaging rather than conventional X-ray guidance.

Little Green Pharma (ASX:LGP) occupies one of the more speculative areas of the ASX healthcare sector: medicinal cannabis, with an emerging psychedelics angle. The company cultivates cannabis and manufactures medicinal cannabis products for patients in Australia and Europe, while also developing psilocybin-assisted therapy aimed …

Emyria (ASX:EMD) is a small Australian healthcare company operating at the frontier of mental-health treatment, and that positioning makes it an interesting, if speculative, watchlist name. The company is focused on delivering and developing new treatments for mental health and selected neurological conditions, a …

• New CFO also announced around the results period

•Operating Cash Flowof US$3.5 billion demonstrates underlyingBusinessstrength

Telix Pharmaceuticals (ASX: TLX) has grown from a speculative radiopharmaceutical hopeful into one of the ASX's larger and better-followed healthcare names, and a September 2026 clinical milestone has put its pipeline back at the centre of the story. On 2 September 2026, the company …